Arformoterol Tartrate

Arformoterol Tartrate (CAS No.: 200815-49-2) is a synthetic small molecule adrenergic ligand in the phenylethanolamine class and represents the tartrate salt of the R,R enantiomer of formoterol, broadly categorized as a long acting beta2 adrenergic receptor agonist for respiratory pharmacology research and translational drug discovery workflows. In mechanistic studies, it is primarily characterized by high affinity engagement of beta2 adrenergic receptor signaling, with reported receptor binding in the nanomolar range and downstream activation of canonical Gs protein coupled pathways that elevate intracellular cyclic AMP and stimulate protein kinase A dependent signaling networks, enabling investigation of receptor desensitization, biased signaling behavior, smooth muscle tone regulation, and stimulus response dynamics in airway relevant systems. Based on available pharmacology for this molecular class, functional activity is generally assessed from nanomolar to micromolar concentration windows depending on assay format, receptor expression context, and readout sensitivity, and it is commonly used in cell based assays expressing beta adrenergic receptors, ex vivo airway tissue reactivity platforms, and animal models of pulmonary function to benchmark bronchodilatory pathway modulation and to support comparative profiling of beta2 adrenergic agonists in screening cascades. Typical concentrations or doses used in experiments depend on specific experimental designs and research objectives, including endpoint selection, exposure duration, species differences, and combination with pathway specific probes, and the compound is therefore principally positioned as a reference pharmacological tool for receptor biology, signaling pathway mapping, and preclinical mechanism focused research use only.